WAVEMAN · COMPANY

AVNT · Avient Corp

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

AVNT

Name: AVIENT CORP (AVNT) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

AVIENT CORP

PHARMA & BIOTECH · PLASTIC MATERIALS, SYNTH RESINS & NONVULCAN ELASTOMERS · CIK 0001122976

CONGRESS · 1FORM 144 · 1☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

189

13F, latest reported quarter

REVENUE GROWTH

+0.6%

XBRL, annual

NET MARGIN

2.5%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

1 member bought in the last year

the lowest in Pharma & Biotech

FUNDS

189 funds added or opened last quarter

more than 86% of Pharma & Biotech

REVENUE

+0.6% year over year

below 53% of Pharma & Biotech

MARGIN

2.5% net margin

more than 70% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

4.4% of shares outstanding short · 5.9 days to cover · settled 2026-07-31

more than 50% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

189 funds added or opened positions in the latest 13F quarter, of 348 holders.

1 member of Congress reported buying it this year.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +22.3%

+22.3%12M

FORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows 189 funds added last quarter, 1 Congress member(s) bought in 12 months, $1.9M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for AVIENT CORP in the period covered. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Rathbun Joel R.

SVP, Mergers & Acquisitions

SELL

2024-11-07

5,762.0

$296.5K

Rathbun Joel R.

SVP, Mergers & Acquisitions

SELL

2024-08-07

11,698.0

$507.2K

Patterson Robert M

Chairman, President & CEO

BUY

2023-11-17

24,304.0

$839.7K

Rathbun Joel R.

SVP, Mergers & Acquisitions

SELL

2023-09-06

6,743.0

$262.8K

Kunkle Lisa K.

SVP Gnrl Counsel & Secretary

SELL

2021-11-16

11,447.0

$689.3K

5 TRANSACTIONS ON RECORD · THIN RECORD, READ IT AS SUCH

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

11,823,646.0 sh

$437.0M

VANGUARD PORTFOLIO MANAGEMENT LLC

5,689,026.0 sh

$210.3M

DIMENSIONAL FUND ADVISORS LP

5,261,081.0 sh

$194.4M

VANGUARD CAPITAL MANAGEMENT LLC

4,124,750.0 sh

$152.5M

STATE STREET CORP

3,846,793.0 sh

$143.2M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Beggs Jamie A.

FILED 2026-08-07

$1.9M

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Franklin Small Cap Value VIP Fund

$31.1M POSITION · AS OF 2026-03-31

2.7%

Small Cap Special Values Fund

$4.5M POSITION · AS OF 2026-02-28

2.6%

Brighthouse Small Cap Value Portfolio

$17.3M POSITION · AS OF 2026-03-31

2.5%

Allspring Special Small Cap Value Fund

$76.2M POSITION · AS OF 2026-03-31

2.4%

LVIP Channing Small Cap Value Fund

$2.2M POSITION · AS OF 2026-03-31

2.2%

CHANNING INTRINSIC VALUE SMALL-CAP FUND

$235.1K POSITION · AS OF 2026-04-30

2.1%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$3.3B	$3.2B	$3.1B	$3.4B
GROSS PROFIT	$1.0B	$1.1B	$892.5M	$882.7M
OPERATING INCOME	$203.5M	$329.3M	$196.8M	$243.3M
NET INCOME	$81.9M	$169.5M	$75.7M	$703.1M
EPS (DILUTED)	0.89	1.84	0.83	7.63
OPERATING CASH FLOW	$301.6M	$256.8M	$201.6M	$398.4M
LONG-TERM DEBT	$1.9B	$2.1B	$2.1B	$2.2B
BUYBACKS	—	$0	$0	$36.4M
DIVIDENDS PAID	$98.8M	$94.0M	$90.2M	$86.8M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE